BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Moderna readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Moderna's drugs run\, from Clinic
 alTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06305767-2042@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20270423
DTEND;VALUE=DATE:20270424
SUMMARY:Intismeran Autogene: Phase 1/2 readout est. (NCT06305767)
DESCRIPTION:Intismeran Autogene\, phase 1/2.\nStudy: A Clinical Study of In
 tismeran Autogene (V940) Treatment and Pembrolizumab in People With Bladde
 r Cancer (V940-005/INTerpath-005)\nEstimated primary completion: 23 April 
 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/intismeran-auto
 gene#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T06305767
URL:https://assetmemo.bio/drug/intismeran-autogene#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06307431-2042@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20280108
DTEND;VALUE=DATE:20280109
SUMMARY:Intismeran Autogene: Phase 2 readout est. (NCT06307431)
DESCRIPTION:Intismeran Autogene\, phase 2.\nStudy: A Study of Adjuvant Inti
 smeran Autogene (V940) and Pembrolizumab in Renal Cell Carcinoma (V940-004
 ).\nEstimated primary completion: 8 January 2028. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/intismeran-autogene#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT06307431
URL:https://assetmemo.bio/drug/intismeran-autogene#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06961006-2042@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20280722
DTEND;VALUE=DATE:20280723
SUMMARY:Intismeran Autogene: Phase 2 readout est. (NCT06961006)
DESCRIPTION:Intismeran Autogene\, phase 2\, Melanoma.\nStudy: A Clinical St
 udy of Intismeran Autogene (V940) and Pembrolizumab (MK-3475) in People Wi
 th Melanoma (V940-012/INTerpath-012)\nEstimated primary completion: 22 Jul
 y 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/intismeran-au
 togene#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT06961006
URL:https://assetmemo.bio/drug/intismeran-autogene#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07221474-2042@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20290702
DTEND;VALUE=DATE:20290703
SUMMARY:Intismeran Autogene: Phase 2 readout est. (NCT07221474)
DESCRIPTION:Intismeran Autogene\, phase 2\, Non-Small Cell Lung Cancer.\nSt
 udy: A Study of Intismeran Autogene (V940)/Placebo + Pembrolizumab and Che
 motherapy in Metastatic Squamous Non-Small Cell Lung Cancer (V940-013)\nEs
 timated primary completion: 2 July 2029. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/intismeran-autogene#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT07221474
URL:https://assetmemo.bio/drug/intismeran-autogene#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05933577-2042@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20291026
DTEND;VALUE=DATE:20291027
SUMMARY:Intismeran Autogene: Phase 3 readout est. (NCT05933577)
DESCRIPTION:Intismeran Autogene\, phase 3\, Melanoma.\nStudy: A Clinical St
 udy of Intismeran Autogene (V940) Plus Pembrolizumab in People With High-R
 isk Melanoma (V940-001)\nEstimated primary completion: 26 October 2029. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/intismeran-autogene#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0593357
 7
URL:https://assetmemo.bio/drug/intismeran-autogene#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07116616-3373@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20300617
DTEND;VALUE=DATE:20300618
SUMMARY:mRNA-2808: Phase 1/2 readout est. (NCT07116616)
DESCRIPTION:mRNA-2808\, phase 1/2\, Multiple Myeloma.\nStudy: A Study of mR
 NA-2808 in Participants With Relapsed or Refractory Multiple Myeloma\nEsti
 mated primary completion: 17 June 2030. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/mrna-2808#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT07116616
URL:https://assetmemo.bio/drug/mrna-2808#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06077760-2042@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20300625
DTEND;VALUE=DATE:20300626
SUMMARY:Intismeran Autogene: Phase 3 readout est. (NCT06077760)
DESCRIPTION:Intismeran Autogene\, phase 3\, Non-Small Cell Lung Cancer.\nSt
 udy: A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Ve
 rsus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung C
 ancer (V940-002)\nEstimated primary completion: 25 June 2030. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/intismeran-autogene#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT06077760
URL:https://assetmemo.bio/drug/intismeran-autogene#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06833073-2042@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20310903
DTEND;VALUE=DATE:20310904
SUMMARY:Intismeran Autogene: Phase 2 readout est. (NCT06833073)
DESCRIPTION:Intismeran Autogene\, phase 2.\nStudy: A Clinical Study of Inti
 smeran Autogene (V940) and BCG in People With Bladder Cancer (V940-011/INT
 erpath-011)\nEstimated primary completion: 3 September 2031. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/intismeran-autogene#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT06833073
URL:https://assetmemo.bio/drug/intismeran-autogene#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03897881-2042@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20321121
DTEND;VALUE=DATE:20321122
SUMMARY:Intismeran Autogene: Phase 2 readout est. (NCT03897881)
DESCRIPTION:Intismeran Autogene\, phase 2\, Melanoma.\nStudy: An Efficacy S
 tudy of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 
 and Pembrolizumab in Participants With High-Risk Melanoma (KEYNOTE-942)\nE
 stimated primary completion: 21 November 2032. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/intismeran-autogene#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT03897881
URL:https://assetmemo.bio/drug/intismeran-autogene#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06623422-2042@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20330516
DTEND;VALUE=DATE:20330517
SUMMARY:Intismeran Autogene: Phase 3 readout est. (NCT06623422)
DESCRIPTION:Intismeran Autogene\, phase 3\, Non-Small Cell Lung Cancer.\nSt
 udy: A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogen
 e (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpa
 th-009)\nEstimated primary completion: 16 May 2033. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/intismeran-autogene#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT06623422
URL:https://assetmemo.bio/drug/intismeran-autogene#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07513376-2042@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20340822
DTEND;VALUE=DATE:20340823
SUMMARY:Intismeran Autogene: Phase 3 readout est. (NCT07513376)
DESCRIPTION:Intismeran Autogene\, phase 3\, Non-Small Cell Lung Cancer.\nSt
 udy: A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembro
 lizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk S
 tage I Non-Small Cell Lung Cancer (V940-014)\nEstimated primary completion
 : 22 August 2034. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/int
 ismeran-autogene#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT07513376
URL:https://assetmemo.bio/drug/intismeran-autogene#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
